Skip to text Skip to main menu

SCIENCE & TECHNOLOGY

ABBIO’S CORE TECHNOLOGIES : (ADVANCED) sCAR-T TECH

Switchable CAR-T (sCAR-T) technology

Antibodies : Humanized antibody

Tag (FITC) : No tag receptor in human body
Less immunogenicity

Switch Molecule (SM)

Switch molecule is engineered by conjugating FITC
to a monoclonal antibody targeting TAAs, enabling
it to bridge tumor cells with sCAR-T cells

Switchable CAR-T cell (sCAR-T)

sCAR-T cell is engineered to express anti-FITC scFvs that target the FITC on the switch molecule, and eliminates tumors through the formation of immune synapse mediated by SM

We aim to develop and expand our therapeutic pipelines to achieve complete remission with minimal adverse events across various tumors. This effort is driven by our sCAR-T technology, whose mechanism of action and efficacy have been rigorously validated through a series of prior in-house research and development, including IIT studies

  • Prevention of
    T Cell Exhaustion
  • Mitigation of
    Adverse Events
  • Targeting
    Multiple Antigens

Basic mechanism of action of sCAR-T

The formation of immune synapse (IS) is mediated by SM

By fine-tuning the dosage of SM, sCAR-T cytotoxicity can be sustained while minimizing severe side effects, enabling the efficient elimination of cancer cells.

In the case of heterogeneous solid tumors
or antigen downregulated hematologic malignancies
View More

Case 1 : As tumors are heterogeneous, tumor cells may evade from the attack of CAR-T targeting a single TAA on the tumor

Case 2 : As antigen downregulation occurs at tumor side, conventional CAR-T can not recognize target tumor antigen

However, tumor cells can be eradicated by sCAR-T with administration of SMs targeting a variety of antigens (Case 1) or another SM targeting different antigens (Case 2) without manufacturing of additional CAR-T

In the event of on-target, off-tumor toxicity
View More

When on-target, off-tumor toxicity arises, the
activity of sCAR-T cells can be effectively
suppressed by administering an FITC solution or
FITC-conjugated IgG isotype to the patient

Reactivation of sCAR-T cells can be achieved
through the re-administration of the SM